Posted by Michael Wonder on 27 Jun 2022
Trastuzumab deruxtecan recommended for approval in the EU by CHMP for patients with HER2 positive metastatic breast cancer treated with a prior anti-HER2 based regimen
27 June 2022 - Recommendation based on DESTINY-Breast03 trial results showing Daiichi Sankyo and AstraZeneca’s trastuzumab deruxtecan reduced the risk of disease progression or death by 72% vs. trastuzumab emtansine.
Daiichi Sankyo and AstraZeneca’s trastuzumab deruxtecan has been recommended for approval in the European Union as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive breast cancer who have received one or more prior anti-HER2 based regimens.
